Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Recombinant RSV Vaccine in Adults
NCT07807449Phase 1Not yet recruiting
- Sponsor
- Yikang Biotech
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant RSV vaccine (CHO cell) in respiratory syncytial virus infection (RSV) (10 arms), sponsored by Yikang Biotech. Primary endpoints: Incidence of immediate adverse events at 30 minutes, Incidence of solicited adverse events at 14 days and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
recombinant RSV vaccine (CHO cell)
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07807449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807449.